Long-Term Analysis of CT041 (Satricabtagene Autoleucel) in Advanced Gastric Cancer Presented at 2026 ASCO Annual Meeting

Stock News06-01

CARSGEN-B (02171) announced that research findings on satricabtagene autoleucel injection (product code: CT041, an autologous CAR-T cell therapy candidate targeting Claudin18.2 protein) were presented in a poster session at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. The presentation, held from 13:30 to 16:30 Central Daylight Time on May 30, 2026, featured long-term analysis results of the therapy as a sequential treatment following first-line therapy in patients with advanced gastric cancer/gastroesophageal junction adenocarcinoma (G/GEJA).

Further details are available on the company's official website. The abstract presented at the 2026 ASCO meeting is titled "Long-term Follow-up of Satricabtagene Autoleucel (Satri-cel) as Sequential Therapy After First-Line Treatment for Advanced Gastric Cancer – a Subgroup Analysis."

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1174600315?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-01 08:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1174600315","market":"fut","top_or_hot":-1,"title":"Long-Term Analysis of CT041 (Satricabtagene Autoleucel) in Advanced Gastric Cancer Presented at 2026 ASCO Annual Meeting","media":"Stock News","content":"<p>CARSGEN-B (02171) announced that research findings on satricabtagene autoleucel injection (product code: CT041, an autologous CAR-T cell therapy candidate targeting Claudin18.2 protein) were presented in a poster session at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. The presentation, held from 13:30 to 16:30 Central Daylight Time on May 30, 2026, featured long-term analysis results of the therapy as a sequential treatment following first-line therapy in patients with advanced gastric cancer/gastroesophageal junction adenocarcinoma (G/GEJA).</p>\n<p>Further details are available on the company's official website. The abstract presented at the 2026 ASCO meeting is titled \"Long-term Follow-up of Satricabtagene Autoleucel (Satri-cel) as Sequential Therapy After First-Line Treatment for Advanced Gastric Cancer – a Subgroup Analysis.\"</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Long-Term Analysis of CT041 (Satricabtagene Autoleucel) in Advanced Gastric Cancer Presented at 2026 ASCO Annual Meeting</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLong-Term Analysis of CT041 (Satricabtagene Autoleucel) in Advanced Gastric Cancer Presented at 2026 ASCO Annual Meeting\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-06-01 08:30</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>CARSGEN-B (02171) announced that research findings on satricabtagene autoleucel injection (product code: CT041, an autologous CAR-T cell therapy candidate targeting Claudin18.2 protein) were presented in a poster session at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. The presentation, held from 13:30 to 16:30 Central Daylight Time on May 30, 2026, featured long-term analysis results of the therapy as a sequential treatment following first-line therapy in patients with advanced gastric cancer/gastroesophageal junction adenocarcinoma (G/GEJA).</p>\n<p>Further details are available on the company's official website. The abstract presented at the 2026 ASCO meeting is titled \"Long-term Follow-up of Satricabtagene Autoleucel (Satri-cel) as Sequential Therapy After First-Line Treatment for Advanced Gastric Cancer – a Subgroup Analysis.\"</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1574","symbol_name":"生物医药B类股","start_time":0,"source_url":"","article_id":"1174600315","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1174600315","pubTimestamp":1780273818,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"CARSGEN-B (02171) announced that research findings on satricabtagene autoleucel injection (product code: CT041, an autologous CAR-T cell therapy candidate targeting Claudin18.2 protein) were...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1574":"生物医药B类股","BK1585":"昨日强势股","BK1161":"生物科技","BK1587":"次新股","02171":"科济药业-B"},"translate_title":"CT041（Satricabtagene Autoleucel）治疗晚期胃癌的长期分析在2026年ASCO年会上发表","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02171":1},"content_text":"CARSGEN-B (02171) announced that research findings on satricabtagene autoleucel injection (product code: CT041, an autologous CAR-T cell therapy candidate targeting Claudin18.2 protein) were presented in a poster session at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. The presentation, held from 13:30 to 16:30 Central Daylight Time on May 30, 2026, featured long-term analysis results of the therapy as a sequential treatment following first-line therapy in patients with advanced gastric cancer/gastroesophageal junction adenocarcinoma (G/GEJA).\nFurther details are available on the company's official website. The abstract presented at the 2026 ASCO meeting is titled \"Long-term Follow-up of Satricabtagene Autoleucel (Satri-cel) as Sequential Therapy After First-Line Treatment for Advanced Gastric Cancer – a Subgroup Analysis.\"","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1174600315","isCrawlerRequest":true}